Page 41 - Annual Report
P. 41

coordinating one of the various sections of the Journal. The Editors   各自統籌不同類型的醫學論文工作,編輯
              nominate reviewers and make recommendations regarding the    則負責提名同行評審人並對已提交的論文
              papers submitted. The Advisors lend their professional expertise to   作出建議,而顧問主要就論文的統計學或
              provide statistical or methodological guidance for submitted papers,   研究方法,以及管理期刊等事宜提供專業
              or other aspects of journal management. Under the leadership of   意見。在總編輯領導下,編委會為雜誌制
              the Editor-in-Chief, the Editorial Board establishes and defines the   定政策,決定送審或退稿,以及為作者、
              policies of the Journal; makes editorial decisions; and formulates   同行評審人和編輯部人員制定清晰明確的
              clear guidelines for authors, reviewers, and the editorial office   指引,確保雜誌順利運作。編委會致力提
              to ensure smooth operation of the Journal. The Editorial Board   高雜誌的質量和相關性,包括加快處理當
              members are committed to enhancing the quality and relevance of   前熱門話題之文章和嚴謹審查已提交文章
              the Journal by expediting articles on current hot topics and applying   的研究方法。
              rigorous methodological review of submitted articles.




              Improving Impact Factor                                      提升中的學術影響力

              The Hong Kong Academy of Medicine Press is delighted that the   《香港醫學雜誌》的學術影響力持續提升。
              Impact Factor of the HKMJ has again increased. The 2021 Journal   2022 年科睿唯安期刊引證報告顯示,2021
              Impact Factor is 3.125 (Clarivate Analytics, 2022), and the 2021   年《香港醫學雜誌》的影響系數為 3.125;
              CiteScore is 2.0 (Scopus, 2022). Appreciation goes to all Editorial   2022 年 Scopus 期刊評價指標報告顯示
              Board members, authors, and reviewers for their unwavering   2021 年《香港醫學雜誌》CiteScore 的系
              support.                                                     數為 2.0。醫專感謝編委會、作者和同行
                                                                           評審人的積極參與和貢獻。



              Prize for Best Original Research by Young Fellows (BORYF)    《最佳年青院士原創研究獎》

              The Prize for Best Original Research by Young Fellows was    《 最佳年 青院 士原 創研 究獎 》設 立
              successfully launched in 2019, with an aim to recognise excellence   於 2019 年,旨在表揚年青院士的卓越
              in outstanding research conducted and led by young Fellows.   學術研究成就。初審小組選出評分最
              The submissions were assessed by an Evaluation Panel, and the   高的五篇文章摘要,繼而由總評審團
              highest-rated abstracts were selected as finalists. Esteemed   評審文章全文並選出三名得獎者。得
              invited Final Judges assessed the full papers of the five finalists   獎者包括(金獎)香港病理學專科學
              and chose the three final winners. The winners of the 2021 Prize   院陳福和醫生及其團隊,研究題目為
              for Best Original Research by Young Fellows were: Dr. Jasper Fuk-  Simulation of the Clinical and Pathological
              woo Chan (from College of Pathologists) who won the Gold medal   Manifestations of Coronavirus Disease 2019
              for his team’s research ‘Simulation of the Clinical and Pathological   (COVID-19) in a Golden Syrian Hamster
              Manifestations of Coronavirus Disease 2019 (COVID-19) in     Model: Implications for Disease Pathogenesis
              a Golden Syrian Hamster Model: Implications for Disease      and Transmissibility、(銀獎)香港眼科
              Pathogenesis and Transmissibility’; Dr. Mary Ho (from College   醫學院何璟穎醫生及其團隊,研究題
              of Ophthalmologists) who won the Silver medal for her team’s   目為 Analysis of choriocapillaris perfusion
              study ‘Analysis of choriocapillaris perfusion and choroidal layer   and choroidal layer changes in patients with
              changes in patients with chronic central serous chorioretinopathy   chronic central serous chorioretinopathy
              randomised to micropulse laser or photodynamic therapy’; and   randomised to micropulse laser or
              Dr. Michael Shing-fung Lee (from College of Radiologists) who   photodynamic therapy,以及(銅獎)香港
              won the Bronze medal for his team’s research ‘Doxorubicin and   放射科醫學院李成峰醫生及其團隊,研
              subsequent risk of cardiovascular diseases among survivors of   究題目為 Doxorubicin and subsequent risk
              diffuse large B-cell lymphoma in Hong Kong’.                 of cardiovascular diseases among survivors of
                                                                           diffuse large B-cell lymphoma in Hong Kong。









 38  HKAM Annual Report 2022                                                       香港醫學專科學院 2022 年度報告              39
   36   37   38   39   40   41   42   43   44   45   46